1.
Correlation between factors and clinicopathological characteristics in the 74 patients with HCC.
| Clinicopathological variables | Total | p-FAK† | P | cPLA2α† | P | |||
| Low (%) | High (%) | Low (%) | High (%) | |||||
| †Final staining score ≤ 3 was defined as low expression; final staining score > 3 was defined as high expression. *P < 0.05 was considered statistically significant. Abbreviations: AFP, alpha fetoprotein; ALB, albumin; HBV, hepatitis B virus; HCV, hepatitis C virus; MVI, microvascular invasion; MAVI, macrovascular invasion. | ||||||||
| Age (years) | ≤ 55 | 43 | 25 (58.1%) | 18 (41.9%) | 0.409 | 31 (72.1%) | 12 (27.9%) | 0.331 |
| > 55 | 31 | 15(48.4%) | 16 (51.6%) | 19 (61.3%) | 12 (38.7%) | |||
| Gender | Male | 60 | 31(51.7%) | 29 (48.3%) | 0.397 | 43 (71.7%) | 17 (28.3%) | 0.121 |
| Female | 14 | 9(64.3%) | 5 (35.7%) | 7 (50.0%) | 7 (50.0%) | |||
| AFP (μg/L) | ≤ 400 | 47 | 27(57.4%) | 20 (42.6%) | 0.443 | 33 (70.2%) | 14 (29.8%) | 0.524 |
| > 400 | 27 | 13(48.1%) | 14 (51.9%) | 17 (63.0%) | 10 (37.0%) | |||
| ALB (g/L) | ≤ 40 | 25 | 14(56.0%) | 11 (44.0%) | 0.812 | 17 (68.0%) | 8 (32.0%) | 0.955 |
| > 40 | 49 | 26 (53.1%) | 23 (46.9%) | 33 (67.3%) | 16 (32.7%) | |||
| Tumor size (cm) | ≤ 5 | 35 | 25 (71.4%) | 10 (28.6%) | 0.005* | 27 (77.1%) | 8 (22.9%) | 0.098 |
| > 5 | 39 | 15 (38.5%) | 24 (61.5%) | 23 (59.0%) | 16 (41.0%) | |||
| Tumor number | ≤ 1 | 58 | 35 (60.3%) | 23(39.7%) | 0.040* | 41 (70.7%) | 17 (29.3%) | 0.278 |
| > 1 | 16 | 5 (31.3%) | 11(68.7%) | 9 (56.3%) | 7 (43.7%) | |||
| HBV | Absent | 21 | 9 (42.9%) | 12 (57.1%) | 0.227 | 17 (81.0%) | 4 (19.0%) | 0.124 |
| Present | 53 | 31 (58.5%) | 22 (41.5%) | 33 (62.3%) | 20 (37.7%) | |||
| HCV | Absent | 68 | 39 (57.4%) | 29 (42.6%) | 0.057 | 47 (69.1%) | 21 (30.9%) | 0.341 |
| Present | 6 | 1 (16.7%) | 5 (83.3%) | 3(50.0%) | 3 (50.0%) | |||
| Liver cirrhosis | Absent | 38 | 18 (47.4%) | 20 (52.6%) | 0.239 | 23 (60.5%) | 15 (39.5%) | 0.187 |
| Present | 36 | 22 (61.1%) | 14 (38.9%) | 27 (75.0%) | 9 (25.0%) | |||
| Tumor encapsulation | Absent | 70 | 37 (52.9%) | 33 (47.1%) | 0.391 | 46 (65.7%) | 24 (34.3%) | 0.157 |
| Present | 4 | 3 (75.0%) | 1 (25.0%) | 4 (100%) | 0 (0%) | |||
| Tumor thrombus | Absent | 26 | 14 (53.8%) | 12 (46.2%) | 0.979 | 18 (69.2%) | 8 (30.8%) | 0.823 |
| Present | 48 | 26 (54.2%) | 22 (45.8%) | 32 (66.7%) | 16 (33.3%) | |||
| Satellite node | Absent | 48 | 30 (62.5%) | 18 (37.5%) | 0.049* | 33 (68.8%) | 15 (31.2%) | 0.769 |
| Present | 26 | 10 (38.5%) | 16 (61.5%) | 17 (65.4%) | 9 (34.6%) | |||
| MVI | Absent | 70 | 37 (52.9%) | 33 (47.1%) | 0.391 | 47 (67.1%) | 23 (32.9%) | 0.746 |
| Present | 4 | 3 (75.0%) | 1 (25.0%) | 3 (75.0%) | 1 (25.0%) | |||
| MAVI | Absent | 68 | 37 (54.4%) | 31 (45.6%) | 0.836 | 50 (73.5%) | 18 (26.5%) | 0.000* |
| Present | 6 | 3 (50.0%) | 3 (50.0%) | 0 (0%) | 6 (100%) | |||
| p-FAK | Low | 40 | 31 (77.5%) | 9 (22.5%) | 0.049* | |||
| High | 34 | 19 (55.9%) | 15 (44.1%) | |||||
| cPLA2α | Low | 50 | 31 (62.0%) | 19 (38.0%) | 0.049* | |||
| High | 24 | 9 (37.5%) | 15 (62.5%) | |||||